GB-68967 | August 2025
For UK HCPs only.
Click here for references and abbreviations.
Click here for prescribing information and adverse event reporting information.
Find out more
BTS/NICE/SIGN 2024 guideline
now published and recommending
ICS/Formoterol across the asthma pathway for new patients aged 12 and over.1
BTS/NICE/SIGN 2024 guideline
now published and recommending
ICS/Formoterol across the asthma pathway for new patients aged 12 and over.1
Find out more
For UK HCPs only.
Click here for references and abbreviations.
Click here for prescribing information and adverse event reporting information.
Find out more
BTS/NICE/SIGN 2024 guideline
now published and recommending
ICS/Formoterol across the asthma pathway for new patients aged 12 and over.1
Symbicort® (budesonide/formoterol)
Turbohaler®
Find out more
with you every step of the way
from age 12 and over – as per 2024 BTS/NICE/SIGN guideline 1
Reliever Therapy (200/6 only)3 & MART (100/6 & 200/6 only) 2,3
GB-68967 | August 2025
GB-68967 | August 2025
For UK HCPs only.
Click here for references and abbreviations.
Click here for prescribing information and adverse event reporting information.
Symbicort® (budesonide/formoterol) Turbohaler® 100/6 and 200/6 are indicated for adults and adolescents 12 years and older for regular treatment of asthma where the combined use of inhaled corticosteroids (ICS) and long-acting β2 adrenoceptor agonist (LABA) is appropriate:2,3
- Patients not adequately controlled with ICS and as needed inhaled short-acting β2 adrenoceptor agonists (SABA); or -Patients already adequately controlled on both ICS and LABA.
Symbicort® Turbohaler® 100/6 is not intended for the initial management of asthma. It is also indicated in children with moderate asthma aged ≥6 years for regular maintenance treatment with a separate rapid-acting bronchodilator as rescue. Note: This inhaler is not appropriate in patients with severe asthma.2
Symbicort® Turbohaler® 200/6 is also indicated as reliever therapy for adults and adolescents ≥12 years with mild asthma.3
Symbicort® Turbohaler® 100/6 (moderate asthma only) or 200/6 (moderate or severe asthma) are indicated for Maintenance And Reliever Therapy (MART) or for maintenance therapy in asthma patients ≥12 years.2,3
For further information, maximum dosage and method of administration for Symbicort® Turbohaler® 100/6 and 200/6, see SmPCs.2,3